Gasparini Roberto, Amicizia Daniela, Domnich Alexander, Lai Piero Luigi, Panatto Donatella
Department of Health Sciences, University of Genoa, Genoa, Italy.
Expert Rev Vaccines. 2014 Mar;13(3):345-64. doi: 10.1586/14760584.2014.880341. Epub 2014 Jan 29.
Since the development of the first-generation vaccines based on outer membrane vesicles (OMV), which were able to contain strain-specific epidemics, but were not suitable for universal use, enormous steps forward in the prevention of Neisseria meningitidis B have been made. The first multicomponent vaccine, Bexsero(®), has recently been authorized for use; other vaccines, bivalent rLP2086 and next-generation OMV vaccines, are under development. The new vaccines may substantially contribute to reducing invasive bacterial infections as they could cover most Neisseria meningitidis B strains. Moreover, other potentially effective serogroup B vaccine candidates are being studied in preclinical settings. It is therefore appropriate to review what has recently been achieved in the prevention of disease caused by serogroup B.
自第一代基于外膜囊泡（OMV）的疫苗研发以来，该疫苗虽能控制特定菌株的流行，但不适合广泛使用，在预防B群脑膜炎奈瑟菌方面已取得了巨大进展。首款多组分疫苗Bexsero(®)最近已获批使用；其他疫苗，如二价rLP2086和下一代OMV疫苗，也正在研发中。这些新疫苗可能会极大地有助于减少侵袭性细菌感染，因为它们可以覆盖大多数B群脑膜炎奈瑟菌菌株。此外，其他潜在有效的B群血清型疫苗候选物正在临床前研究中。因此，回顾一下最近在预防B群血清型引起的疾病方面所取得的成果是恰当的。
